CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus
Authors
A Oku
A Ptaszynska
+48 more
B Komoroski
C Baylis
CC Newton
CJ Bailey
D Bansal
DB Clayson
E Ferrannini
EA Gehan
EI Wallner
ET Gaillard
FD Sistare
GC Hard
GC Hard
H Maeshima
H Maeshima
H Osorio
I Sabolic
IF Tannock
J Bolinder
J Chen
J Mandell
J Rosenstock
JA Nelson
JA Nelson
JF List
JI Everitt
JP Wilding
JP Wilding
JR Bucher
K Maita
K Strojek
L Zhang
LA Buckley
M Bhartia
M Obermeier
M Tirmenstein
MA Nauck
PJ Hardefeldt
R Santer
S Han
S Kasichayanula
S Kasichayanula
SA Jabbour
V Vallon
W Meng
WC Son
WN Washburn
Y Kanai
Publication date
Publisher
'Springer Science and Business Media LLC'
Doi
Cite
Abstract
Abstract is not available.
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
info:doi/10.1007%2Fs13300-014-...
Last time updated on 05/06/2019